Trending...
- California: Governor Newsom proclaims Independence Day 2025
- New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
- Transgender Visual Artist Debuts New Work
Ventura & Associates HTA Advisors, an advancing strategy consulting and tech-enabled solutions firm, has announced a landmark 3-year RWD agreement to accelerate a clinical research analysis tool.
LOS ANGELES - Californer -- Ventura & Associates HTA Advisors, a California-based strategy consulting and tech-enabled solutions firm, has announced a landmark 3-year agreement with the National Clinical Trials Network (NCTN) to accelerate the development of an innovative clinical research analysis tool. This strategic partnership will leverage the power of real-world data (RWD) to drive groundbreaking discoveries and deeper insights into the understanding and treatment of complex medical conditions.
By combining the company's expertise in data-driven solutions with the NCTN's extensive clinical research network, this collaboration promises to revolutionize the way medical breakthroughs are achieved. The advanced analytics platform being developed will augment researchers' abilities to uncover patterns, trends and correlations within vast datasets, unlocking unprecedented opportunities for innovation.
More on The Californer
Ventura, CEO, has been incubating the project, stating, "We are honored to partner with the NCTN and that they see merit in the research to in turn leverage our collective capabilities to advance the frontiers of clinical research. The data acquired under this agreement spans five oncology studies will play a critical role in validating the design of the product and really bringing the plans to life. We are working on a second agreement to obtain more, relevant RWD areas in other therapeutic areas specifically in Diabetes and Alzheimer's Disease due to the adherence challenges and use of quality-of-life outcomes, as well as other studies with complex designs. We later plan to present our findings in the interim at a conferences during the terms of the agreements. We are actively seeking investors and additional research partners in Pharma & Biotech. All research and data management are HIPAA-compliant."
This agreement solidifies the start-up's position as a leading provider of tech-enabled solutions in the pharmaceutical industry. The partnership with major, global pharmaceutical companies positions the company at the forefront of innovation. This strategic alliance underscores the company's commitment to making meaningful strides in the pre-seed stage and its mission to remain committed to patient centricity and positive change.
More on The Californer
The company is currently seeking early stage investors globally as it accelerates the development of the tech-enabled solution to the minimum viable product (MVP) stage by end of Q2 2025. The company plans to subsequently continue research in predictive modeling and AI. The company sees a noteworthy market opportunity for correlo given the heightened focus on AI and drug development over the past year.
For more information visit the available websites:
Company Website, Latest Investor Presentation
LinkedIn
By combining the company's expertise in data-driven solutions with the NCTN's extensive clinical research network, this collaboration promises to revolutionize the way medical breakthroughs are achieved. The advanced analytics platform being developed will augment researchers' abilities to uncover patterns, trends and correlations within vast datasets, unlocking unprecedented opportunities for innovation.
More on The Californer
- Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations
- AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
- First Partner highlights apprenticeship program helping underrepresented youth break into careers in California's iconic entertainment industry
- Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
- Cal State LA secures funding for two artificial intelligence projects from CSU
Ventura, CEO, has been incubating the project, stating, "We are honored to partner with the NCTN and that they see merit in the research to in turn leverage our collective capabilities to advance the frontiers of clinical research. The data acquired under this agreement spans five oncology studies will play a critical role in validating the design of the product and really bringing the plans to life. We are working on a second agreement to obtain more, relevant RWD areas in other therapeutic areas specifically in Diabetes and Alzheimer's Disease due to the adherence challenges and use of quality-of-life outcomes, as well as other studies with complex designs. We later plan to present our findings in the interim at a conferences during the terms of the agreements. We are actively seeking investors and additional research partners in Pharma & Biotech. All research and data management are HIPAA-compliant."
This agreement solidifies the start-up's position as a leading provider of tech-enabled solutions in the pharmaceutical industry. The partnership with major, global pharmaceutical companies positions the company at the forefront of innovation. This strategic alliance underscores the company's commitment to making meaningful strides in the pre-seed stage and its mission to remain committed to patient centricity and positive change.
More on The Californer
- Colbert Packaging Announces WBENC Recognition
- New Mobile Car Detailing Platform Connects Drivers with On-Demand Local Pros
- Over the past three months, California seized $476 million worth of unlicensed cannabis products
- California scores more clean energy records: 9 in 10 days this year partially powered by 100% clean energy
- "Mobile Suit Gundam" Takes Over San Diego Comic-Con 2025
The company is currently seeking early stage investors globally as it accelerates the development of the tech-enabled solution to the minimum viable product (MVP) stage by end of Q2 2025. The company plans to subsequently continue research in predictive modeling and AI. The company sees a noteworthy market opportunity for correlo given the heightened focus on AI and drug development over the past year.
For more information visit the available websites:
Company Website, Latest Investor Presentation
Source: Ventura & Associates HTA Advisors LLC
Filed Under: Software
0 Comments
Latest on The Californer
- Voices for Humanity Builds a Better Future for Ghana with Richmond Atta-Williams
- Haunted Doll House at The Gregangelo Museum
- Mystical Insights at the Gregangelo Museum
- Ben Pouladian, CEO of BEP Holdings, to Join ISPE Los Angeles Biomanufacturing Panel
- Raksmart: Promoting Security in Global Hosting Service
- $14M Expansion Deal with Famed David Lloyd Highlights Rebrand of Sports, Entertainment and Gaming Innovation by AI Driven, Online Fan Engagement Co
- Local Pub Grows Unique Community Ownership Program
- Heartfelt Dreams Foundation Launches Campaign to Build CHD Hospital
- California: Acting Governor Eleni Kounalakis proclaims Disability Pride Month
- CHRIS EDMONDS JOINS CITY NATIONAL BANK AS EXECUTIVE VICE PRESIDENT, HEAD OF COMMERCIAL AND NATIONAL CORPORATE BANKING
- Radarsign Tackles Intersection Safety with Launch of Grid-Free Solar LED Stop Sign
- California: $35 million to law enforcement partners to keep communities safe from impaired driving
- Curtis Sergeant's Book The Only One Continues to Equip Christians to Live Fully in by and for God
- IFYA Announces New Froyo Heaven Art Contest
- BKM Capital Partners Publishes Case Study on Hughes Airport Center, Showcasing Strategic Value-Add Execution in Las Vegas
- Miami Real Estate Agent Drastically Increases Interest In Homes
- Adostics & Genmega Announce the Introduction of A-POD
- Auto Careers Online Secures Top Dealers' Choice Award for Eighth Consecutive Year
- MANTL Becomes First Fintech to Offer Plaid Layer
- LIB and Nidec Rejoin Forces for Giant TH-0098 Temperature Humidity Test Chamber